Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma.
作者信息
Raedler Lisa A
出版信息
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):70-3.
Abstract
摘要
相似文献
1
Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma.
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):70-3.
2
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707.
3
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
J Oncol Pharm Pract. 2023 Jan;29(1):170-182. doi: 10.1177/10781552221107850. Epub 2022 Jun 20.
4
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Hematology. 2022 Dec;27(1):204-207. doi: 10.1080/16078454.2022.2028978.
5
Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Drugs Today (Barc). 2016 Oct;52(10):551-560. doi: 10.1358/dot.2016.52.10.2543308.
6
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
7
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25.
8
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Biochem Biophys Res Commun. 2021 Jan 15;536:26-31. doi: 10.1016/j.bbrc.2020.12.048. Epub 2020 Dec 22.
9
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Ther Adv Hematol. 2021 Jan 22;12:2040620720987075. doi: 10.1177/2040620720987075. eCollection 2021.
10
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
Ann Pharmacother. 2022 Aug;56(8):927-940. doi: 10.1177/10600280211058754. Epub 2021 Dec 28.
引用本文的文献
1
Leptomeningeal Involvement in Relapsed Multiple Myeloma With Thoracic Spine and Orbital Metastases: A Case Report.
Cureus. 2025 Jun 23;17(6):e86601. doi: 10.7759/cureus.86601. eCollection 2025 Jun.
2
Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution.
BMC Ophthalmol. 2025 Jul 1;25(1):382. doi: 10.1186/s12886-025-04214-5.
3
Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.
Bioact Mater. 2024 Sep 10;42:379-403. doi: 10.1016/j.bioactmat.2024.08.046. eCollection 2024 Dec.
4
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.
Nat Commun. 2024 Aug 11;15(1):6874. doi: 10.1038/s41467-024-50880-2.
5
Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022.
Pharmaceuticals (Basel). 2024 Jun 21;17(7):815. doi: 10.3390/ph17070815.
6
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Int J Mol Sci. 2024 Apr 26;25(9):4718. doi: 10.3390/ijms25094718.
7
Recurrence of solitary plasmacytoma in the liver 10 years after the onset of multiple bone lesions.
J Clin Exp Hematop. 2024;64(1):65-70. doi: 10.3960/jslrt.23056.
8
NADase CD38 is a key determinant of ovarian aging.
Nat Aging. 2024 Jan;4(1):110-128. doi: 10.1038/s43587-023-00532-9. Epub 2023 Dec 21.
9
Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series.
Leuk Lymphoma. 2023 Apr;64(4):900-903. doi: 10.1080/10428194.2023.2183731. Epub 2023 Mar 8.
10
Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.
Transl Oncol. 2022 Nov;25:101532. doi: 10.1016/j.tranon.2022.101532. Epub 2022 Sep 11.
本文引用的文献
1
Multiple myeloma and physical activity: a scoping review.
BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576.
2
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.
3
Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Br J Biomed Sci. 2013;70(3):110-20. doi: 10.1080/09674845.2013.11669945.
4
Novel approaches to treatment of double-refractory multiple myeloma.
Am Soc Clin Oncol Educ Book. 2013;2013:302-6. doi: 10.1200/EdBook_AM.2013.33.e302.
5
New strategies in the treatment of multiple myeloma.
Clin Cancer Res. 2013 Jul 1;19(13):3337-44. doi: 10.1158/1078-0432.CCR-12-1881. Epub 2013 Mar 20.
6
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.
Oncologist. 2013;18(1):27-36. doi: 10.1634/theoncologist.2011-0380. Epub 2013 Jan 8.
7
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Oncologist. 2013;18(1):37-45. doi: 10.1634/theoncologist.2012-0113. Epub 2013 Jan 8.
8
Improved survival in multiple myeloma and the impact of novel therapies.
Blood. 2008 Mar 1;111(5):2516-20. doi: 10.1182/blood-2007-10-116129. Epub 2007 Nov 1.
Zotero 插件